Efficacy of the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen in a phase III trial in the DRC
New England Journal of Medicine — Vol. 394 — N° 3 — pp. e1234
Abstract
A randomized, double-blind, placebo-controlled phase III trial evaluating the efficacy of the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen among healthcare workers and at-risk populations in the Democratic Republic of the Congo.
Authors and affiliations
Bibliographic reference
DOI
10.1056/NEJMoa20261234
PMID
Reference
New England Journal of Medicine
Publication date
2026-02-15